174635-53-1
174635-53-1
Chemical Structure
SB 218795
- CAS No.: 174635-53-1
- Formula:C25H20N2O3
- Molecular Weight:396.44
IUPAC Name: methyl (R)-2-phenyl-2-(2-phenylquinoline-4-carboxamido)acetate
InChIKey: IUMQXQJZIHWLIN-HSZRJFAPSA-N
SMILES: COC([C@@H](C1=CC=CC=C1)NC(C2=CC(C3=CC=CC=C3)=NC4=CC=CC=C24)=O)=O
Biological Activity: SB 218795 is a potent and selective non-peptide NK3 receptor antagonist, with a Ki 13 nM for hNK3. SB 218795 shows about 90-fold and 7000-fold selectivity for hNK3 over hNK2 and hNK1, respectively. SB 218795 can inhibit NK3 receptor-mediated pupillary constriction of the rabbit[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SB 218795 | 99.86% | SB 218795 is a potent and selective non-peptide NK3 receptor antagonist, with a Ki 13 nM for hNK3. SB 218795 shows about 90-fold and 7000-fold selectivity for hNK3 over hNK2 and hNK1, respectively. SB 218795 can inhibit NK3 receptor-mediated pupillary constriction of the rabbit. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB 218795 (Standard) | SB 218795 (Standard) is the analytical standard of SB 218795 (HY-107692). This product is intended for research and analytical applications. SB 218795 is a potent and selective non-peptide NK3 receptor antagonist, with a Ki 13 nM for hNK3. SB 218795 shows about 90-fold and 7000-fold selectivity for hNK3 over hNK2 and hNK1, respectively. SB 218795 can inhibit NK3 receptor-mediated pupillary constriction of the rabbit. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Giardina GA, et, al. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework. J Med Chem. 1997 Jun 6;40(12):1794-807. [Content Brief]
- [2]. Medhurst AD, et, al. In vitro and in vivo characterization of NK3 receptors in the rabbit eye by use of selective non-peptide NK3 receptor antagonists. Br J Pharmacol. 1997 Oct;122(3):469-76. [Content Brief]
